Latest From Brainsway Ltd.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.
The Helsinki-based company had expected stroke rehabilitation to be the first FDA-cleared indication for its Navigated Brain Therapy system, but while more data is collected for that program, it is pursuing a 510(k) clearance for NBS to treat major depressive disorder and plans to build a US salesforce to market NBS for therapeutic indications.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
The registry will collect data from more than 6,000 depression patients treated with transcranial magnetic stimulation at more than 100 different treatment facilities in the US to better understand how the therapy benefits patients in the "real world."
- Medical Devices
- Therapeutic Areas
- Neurology, Nervous System
- Middle East
- Parent & Subsidiaries
- Brainsway Ltd.
- Senior Management
Yaacov Michlin, CEO
Hadar Levy, CFO
Aron Tendler, MD, CMO
Yiftach Roth, PhD, Chief Scientist
Ronen Segal, CTO
Eliran Ron, VP, Global Operations
- Contact Info
Bynet Bldg., 3rd Fl.
19 Hartom St.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.